Search
Filter Results
Displaying 31–40 of 195 for “x-linked”
-
Apr 22, 2022
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
The Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Sep 24, 2021
MeiraGTx and Janssen Recruiting for Phase 3 XLRP Gene Therapy Clinical Trial
Visit www.LUMEOSstudy.com for more information about trial
-
Feb 17, 2021
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
His latest Foundation grant is helping move the drug toward a clinical trial
-
Oct 7, 2020
AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
-
Aug 4, 2020
4D Molecular Therapeutics Launches Phase 1 Clinical Trial for Choroideremia Gene Therapy
Gene therapy delivered by intravitreal injection
-
Jul 17, 2020
A Phase 3 trial for the treatment is planned
-
Feb 7, 2018
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Taking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
-
Jan 9, 2018
Top Retinal Research Advances for 2017
An exciting year in fighting blindness.
-
Dec 20, 2017
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Known as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
-
Sep 27, 2017
The Foundation's Investments Are Filling the Pipeline for Vision-Saving Therapies
In addition to funding promising biotech start-ups, the Foundation Fighting Blindness has played a critical role in developing research talent.